The Codon Capital Approach
It is easy to predict the future of biotechnology, but it is difficult to know who will invent it, what business success it will fuel. How long will it take? What are the key obstacles that stopped others before, where we see a path (or better: multiple paths) forward to a new innovative technology.
Codon Capital knows how to recognize the what ifs with a technical path that enable breakthrough products.
Codon Capital knows how to recognize the what ifs with a technical path that enable breakthrough products.
"Everything is the technology of the future, until it works."
-Karl D. Handelsman, Founder, Codon Capital
-Karl D. Handelsman, Founder, Codon Capital
Therapeutics
Innovation Meeting Unmet Medical Needs
|
Synthetic Biology
Better, Faster, Cheaper Biology
|
Angel Investments
|
Amplyx Pharmaceuticals • Antheia • Araxes Pharma • Arcus Biosciences • Avidity Biosciences • Bolt Threads • Caribou Biosciences • Clear Labs • eGenesis • EpiBiome • Flexus Biosciences • Glycostasis • Good Therapeutics • Jasper Therapeutics • Kumquat Biosciences • Kura Oncology • Oric Pharmaceuticals • Pivot Bio • RAPT Therapeutics • Shattuck Labs • Vaxart • ViewPoint Therapeutics • Zephyrus Biosciences • Zymergen
|
About Codon
In collaboration with scientific founders and entrepreneurs Karl Handelsman fosters early stage life science innovation. He focuses on early stage pre-clinical therapeutic companies and synthetic biology. The Codon Capital process embraces a rigorous approach by entrepreneurs who search for value, translating science into products.
In addition to working with science research organizations such as Stanford, UCSF, and NIH on translational programs, Codon Capital also makes angel investments in seed and series A startups. Surprisingly, some of these entrepreneurs were able to generate exits in under 18 months.
Specialties: Biotech, early stage, company formation.
More: Handelsman's Linked In
In addition to working with science research organizations such as Stanford, UCSF, and NIH on translational programs, Codon Capital also makes angel investments in seed and series A startups. Surprisingly, some of these entrepreneurs were able to generate exits in under 18 months.
Specialties: Biotech, early stage, company formation.
More: Handelsman's Linked In
